Journal article

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

Katharine L Lewis, Collin K Chin, Kate Manos, John Casey, Nada Hamad, Julie Crawford, Shir-Jing Ho, Samar Issa, Andrew Grigg, Peter Wood, Maher K Gandhi, Bryan Do, Loretta Nastoupil, Eliza A Hawkes, Chan Y Cheah

BRITISH JOURNAL OF HAEMATOLOGY | WILEY | Published : 2020

Abstract

Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL with ibrutinib. We analysed 33 patients who received ibrutinib, alone or with other therapies, for PCNSL (n = 9) or SCNSL (n = 24). The objective response rate was 58% (complete response 55%). The median progression-free survival and overall survival for patients with PCNSL were both 3·1 months; for SCNSL, 10·2 and 11·5 months respectively. Only one invasive fungal infection was observed, despite concurrent or recent use of dexamethasone 8-16 mg daily in 14 patients (4..

View full abstract